✦ LIBER ✦

Tu1100 Organ Dysfunction After Delayed Peptide Receptor Radionuclide Therapy in Patients With Metastatic Neuroendocrine Tumors

✍ Scribed by Singh, Maneesh H.; Soulen, Michael C.; Pryma, Daniel A.; Bennett, Bonita J.; Wild, Damian; Nicolas, Guillaume; Teitelbaum, Ursina R.; Metz, David C.

Book ID: 122321125
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 48 KB
Volume: 144
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(13)62816-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival and Response After Peptide Rece

Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

✍ Roelf Valkema; Stanislas Pauwels; Larry K. Kvols; Raffaella Barone; Francois Jam 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 288 KB

Decreased selenium levels after peptide

Decreased selenium levels after peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumours: implications for the antioxidant status

✍ Roy Moncayo; Annette Traeger 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 61 KB

Peptide receptor radionuclide therapy wi

Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

✍ Vinjamuri, S; Gilbert, T M; Banks, M; McKane, G; Maltby, P; Poston, G; Weissman, 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 721 KB